This Literature case, one of 26 cases in a published article, reported by a health care professional, concerns an 
adult patient whose age was between 34-80 years (exact age, gender, and ethnicity were not provided), who was 
involved in a study. 
history included non-small cell lung cancer (NSCLC) stage I1113 (malignant pleural effusion) or stage IV. 
The patient had not re a prior c m  therapy, immunotherapy, biologic therapy, or anfiangiogenic drugs. 
Concomitant medications included cyanocobalamin 1000 mg every nine weeks starting one week before the first 
cycle of pemetrexed. Folic acid 1 mg was also administered orally every day beginning one week before the first 
cycle of pemetrexed. 
The patient received pemetrexed (unknown manufacturer) 500 mg/m2 as a 10 minute intravenous (IV) infusion on 
Print Time: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 86 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
day one immediately followed by carboplatin as a 30 minute IV infusion on day one, and then bevacizumab 15 
mg/kg as a 30-90 minute IV infusion on day one for treatment of advanced nonsquamous NSCLC sometime 
between Sep2005-Dec2009. On an unspecified date, after completing cycle 2, the patient died of respiratory failure 
after aspiration pneumonia in the setting of venous thromboembolic complications. Treatment measures and 
autopsy status were not provided. 
The author related the events to pemetrexed therapy. 
Literature Citation: Stevenson James P, Langer Corey J, Somer Robert A, Evans Tracey L, Rajagopalan Kumar, 
Krieger Kimberly. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and 
carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer. 2012; 118 5580-5587.